207 related articles for article (PubMed ID: 15680375)
1. Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease.
Casey RG; Joyce M; Roche-Nagle G; Chen G; Bouchier-Hayes D
J Surg Res; 2005 Feb; 123(2):176-81. PubMed ID: 15680375
[TBL] [Abstract][Full Text] [Related]
2. Pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates renal injury in an experimental model of ischemia-reperfusion.
Joyce M; Kelly C; Winter D; Chen G; Leahy A; Bouchier-Hayes D
J Surg Res; 2001 Nov; 101(1):79-84. PubMed ID: 11676559
[TBL] [Abstract][Full Text] [Related]
3. Pravastatin attenuates lower torso ischaemia-reperfusion-induced lung injury by upregulating constitutive endothelial nitric oxide synthase.
Joyce M; Kelly CJ; Chen G; Bouchier-Hayes DJ
Eur J Vasc Endovasc Surg; 2001 Apr; 21(4):295-300. PubMed ID: 11359328
[TBL] [Abstract][Full Text] [Related]
4. Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Yu Y; Ohmori K; Chen Y; Sato C; Kiyomoto H; Shinomiya K; Takeuchi H; Mizushige K; Kohno M
J Am Coll Cardiol; 2004 Aug; 44(4):904-13. PubMed ID: 15312879
[TBL] [Abstract][Full Text] [Related]
5. Effect of pravastatin on experimental diabetic wound healing.
Laing T; Hanson R; Chan F; Bouchier-Hayes D
J Surg Res; 2010 Jun; 161(2):336-40. PubMed ID: 20031169
[TBL] [Abstract][Full Text] [Related]
6. Hydroxymethylglutaryl co-enzyme A reductase inhibition attenuates endotoxin-mediated inflammatory responses.
Joyce M; Casey R; Gang C; Winter D; Kelly CJ; Bouchier-Hayes DJ
Br J Surg; 2005 Aug; 92(8):1034-40. PubMed ID: 15931659
[TBL] [Abstract][Full Text] [Related]
7. Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Joyce M; Moore K; Thompson C; Fitzgerald P; Fennessy F; Kelly CJ; Bouchier-Hayes DJ
Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):432-7. PubMed ID: 15015196
[TBL] [Abstract][Full Text] [Related]
8. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy.
Sugimoto H; Shikata K; Matsuda M; Kushiro M; Hayashi Y; Hiragushi K; Wada J; Makino H
Diabetologia; 1998 Dec; 41(12):1426-34. PubMed ID: 9867209
[TBL] [Abstract][Full Text] [Related]
9. Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Blanco S; Vaquero M; Gómez-Guerrero C; López D; Egido J; Romero R
Am J Hypertens; 2005 Apr; 18(4 Pt 1):557-65. PubMed ID: 15831368
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor (VEGF) does not affect early renal changes in a rat model of lean type 2 diabetes.
Schrijvers BF; De Vriese AS; Tilton RG; Van de Voorde J; Denner L; Lameire NH; Flyvbjerg A
Horm Metab Res; 2005 Jan; 37(1):21-5. PubMed ID: 15702434
[TBL] [Abstract][Full Text] [Related]
11. Protective effect of Liuwei Dihuang decoction on early diabetic nephropathy induced by streptozotocin via modulating ET-ROS axis and matrix metalloproteinase activity in rats.
He H; Yang X; Zeng X; Shi M; Yang J; Wu L; Li L
J Pharm Pharmacol; 2007 Sep; 59(9):1297-305. PubMed ID: 17883901
[TBL] [Abstract][Full Text] [Related]
12. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats.
Kamikawa A; Ishii T; Shimada K; Makondo K; Inanami O; Sakane N; Yoshida T; Saito M; Kimura K
Diabetes Metab Res Rev; 2008; 24(4):331-8. PubMed ID: 18088079
[TBL] [Abstract][Full Text] [Related]
13. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production.
Prabhakar S; Starnes J; Shi S; Lonis B; Tran R
J Am Soc Nephrol; 2007 Nov; 18(11):2945-52. PubMed ID: 17928507
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of diabetic nephropathy in rats by an oral antidiabetic material extracted from yeast.
Nakhoul F; Abassi Z; Morgan M; Sussan S; Mirsky N
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S127-31. PubMed ID: 16565236
[TBL] [Abstract][Full Text] [Related]
15. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy.
Li C; Yang CW; Park JH; Lim SW; Sun BK; Jung JY; Kim SB; Kim YS; Kim J; Bang BK
Am J Physiol Renal Physiol; 2004 Jan; 286(1):F46-57. PubMed ID: 14519596
[TBL] [Abstract][Full Text] [Related]
16. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
17. Effects of pravastatin or 12/15 lipoxygenase pathway inhibitors on indices of diabetic nephropathy in an experimental model of diabetic renal disease.
Gad HI
Saudi Med J; 2012 Jun; 33(6):608-16. PubMed ID: 22729114
[TBL] [Abstract][Full Text] [Related]
18. Berberine ameliorates renal injury in streptozotocin-induced diabetic rats by suppression of both oxidative stress and aldose reductase.
Liu WH; Hei ZQ; Nie H; Tang FT; Huang HQ; Li XJ; Deng YH; Chen SR; Guo FF; Huang WG; Chen FY; Liu PQ
Chin Med J (Engl); 2008 Apr; 121(8):706-12. PubMed ID: 18701023
[TBL] [Abstract][Full Text] [Related]
19. Merit of Astragalus polysaccharide in the improvement of early diabetic nephropathy with an effect on mRNA expressions of NF-kappaB and IkappaB in renal cortex of streptozotoxin-induced diabetic rats.
Zhang YW; Wu CY; Cheng JT
J Ethnopharmacol; 2007 Dec; 114(3):387-92. PubMed ID: 17900838
[TBL] [Abstract][Full Text] [Related]
20. Analysis of NO-synthase expression and clinical risk factors in human diabetic nephropathy.
Hohenstein B; Hugo CP; Hausknecht B; Boehmer KP; Riess RH; Schmieder RE
Nephrol Dial Transplant; 2008 Apr; 23(4):1346-54. PubMed ID: 18065828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
